Baudax Bio logo
Baudax Bio BXRX

Quarterly report 2023-Q3
added 11-20-2023

report update icon

Baudax Bio Financial Ratios 2011-2026 | BXRX

Annual Financial Ratios Baudax Bio

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.0 -0.0 -0.2 -2.5 - - - - - - - -

P/S

0.6 0.3 25.2 - - - - - - - - -

EPS

-177.3 -361.2 -142.9 -3.5 -7.9 - - - - - - -

EV (Enterprise Value)

29.8 M 24.5 M 65.6 M 134 M 103 M 95.2 M - - - - - -

EBITDA per Share

-171 -343 -5.74 -4.98 - - - - - - - -

EV/EBITDA

-2.0 0.2 -1.3 - - - - - - - -

PEG

- 0.0 -0.04 - - - - - - - -

P/B

-0.0 0.0 -0.8 -4.8 - - - - - - - -

P/CF

-0.0 -0.0 -0.3 -1.6 - - - - - - - -

ROE %

242.53 -149.47 514.22 194.71 - - - - - - - -

ROA %

-586.07 -37.11 -110.72 -60.05 - - - - - - - -

ROCE %

234.36 -143.70 -110.28 -101.23 - - - - - - - -

Current Ratio

0.3 1.3 2.0 2.6 - - - - - - - -

DSO

126.1 100.2 37.8 - - - - - - - - -

DIO

- 595.6 627.6 - - - - - - - - -

DPO

140.5 382.2 769.8 - - - - - - - - -

Operating Cycle

126.1 695.9 665.3 - - - - - - - - -

Cash Conversion Cycle

-14.3 313.6 -104.5 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Baudax Bio

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.3 -1.51 4.91 - -98.7 -41.95 -126.87 - -7.03 -7.17 -9.46 - 0.64 -1.72 -4.03 - -1.1 -1.13 -0.46 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.21 -1.44 -2.02 - -12.1 -20.9 -75.4 - -6.77 -7.6 -9.08 - -0.66 -1.7 -4.02 - -1.09 -1.12 -0.45 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

52.84 154.79 -92.35 -188.71 -106.88 -145.89 367.40 2118.45 2039.49 1878.70 1749.22 399.07 460.76 601.40 458.97 150.90 150.90 89.21 25.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-49.38 -206.79 -190.63 -211.49 -239.07 -99.85 -102.17 -70.90 -53.90 -9.32 -32.85 -85.92 -104.95 -140.98 -116.20 -46.54 -101.06 -136.54 -117.02 -54.51 -54.51 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

162.21 159.66 4.40 -152.74 -73.72 -9.48 436.60 2077.87 2160.72 2164.56 2012.05 559.69 621.16 599.77 458.70 150.39 150.39 88.92 25.70 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

0.9 0.9 0.5 0.3 0.5 1.1 1.2 1.3 0.8 0.9 1.0 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.3 0.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - 178.1 186.2 124.3 - 104.1 86.7 49.3 - 68.4 13.3 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

- - - - 367.6 1322.9 719.2 - 777.0 492.9 319.6 - 503.2 418.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

14483.3 4240.1 792.5 - 252.0 802.3 334.6 - 385.5 251.1 266.4 - 617.3 512.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - 545.7 1509.0 843.5 - 881.1 579.6 368.9 - 571.7 431.4 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

-14483.3 -4240.1 -792.5 - 293.6 706.7 508.9 - 495.6 328.5 102.5 - -45.6 -81.4 28.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Baudax Bio, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.52 -2.46 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Certara Certara
CERT
$ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA